Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.
- Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment
- Onco-Innovations’ lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability
- Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies
For decades, chemotherapy has carried a basic trade-off. The same drugs that kill cancer cells can also damage healthy tissue, leading to toxicity that can limit dosing, interrupt treatment, and reduce quality of life. Nanomedicine emerged as a strategy to change how a drug distributes throughout the body. By packaging the drug in nanoscale carriers, these formulations keep more drug in circulation long enough to accumulate in tumors, while reducing unnecessary exposure in healthy tissue Early enthusiasm gave way to skepticism as many experimental formulations failed to translate from animal models into clinical products. Now the field appears to be turning a corner, and a growing group of developers is working to define what the next generation of cancer nanomedicine looks like.
A Field Emerging from Skepticism
A 2025 review of clinical cancer nanomedicines published in the Journal of Controlled Release describes a field moving beyond what its authors characterize as a long trough of disillusionment. More than 20 nanomedicine formulations have now reached clinical use.
These products improve the therapeutic index of the drugs they carry, increasing the gap between therapeutic benefit and unwanted toxicity by altering how treatments distribute throughout the body. In doing so, they have measurably improved patient quality of life during treatment.
The review draws a distinction that matters for newer programs. Earlier generations of nanomedicines primarily made existing drugs more tolerable by reducing side effects. The generation now advancing aims to go further, using nanoparticle engineering to enable therapeutic effects that would not be possible with the free drug alone. That shift, from reducing harm to actively improving performance, provides the backdrop for a new wave of oncology development programs.
Where Onco-Innovations Fits
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a Canadian oncology company developing inhibitors of Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks. Blocking PNKP is designed to leave cancer cells unable to repair damage caused by radiation and chemotherapy while also exploiting synthetic lethality in tumors carrying specific gene expression deficiencies.
PNKP inhibition represents an emerging class within the broader DNA Damage Response field, a category that generated more than $7 billion in sales in 2025 and continues expanding beyond established PARP inhibitors.
The company’s lead candidate, ONC010, sits squarely within the newer-generation nanomedicine model. It combines A83B4C63, a small-molecule inhibitor of PNKP, with a proprietary polymer nanodelivery system designed to encapsulate and transport the drug. In animal studies, the formulation slowed tumor growth, demonstrated favorable pharmacokinetics and low observed toxicity, and increased sensitivity to radiation and certain chemotherapies.
Why the Delivery Platform Matters
DNA Damage Response inhibitors have a challenging history. Several promising candidates have struggled with off-target toxicity or poor solubility that complicated dosing and distribution. Onco’s nanoparticle approach is designed to address those specific obstacles. A nanodelivery platform is not a cosmetic add-on in this context; it is a key part of the therapeutic design. The nanoparticle formulation helps solubilize and carry a small-molecule inhibitor that would otherwise be difficult to administer. By extending circulation time, concentrating the drug at the tumor site, and limiting exposure to healthy tissue, the delivery system is intended to widen the gap between therapeutic effect and toxicity, the central objective that has driven decades of nanomedicine development.
The company’s approach also aligns with broader trends identified in the clinical nanomedicine literature, where researchers increasingly view advanced delivery systems not simply as tools for reducing side effects, but as platforms capable of improving therapeutic performance.
A Key Manufacturing Partnership
Recent activity points to a growing focus on the scale-up and analytical framework that next-generation nanomedicines require. In June, Onco signed a non-binding letter of intent with Nanosoft Polymers, a North Carolina polymer company, to negotiate support for scaled polymer synthesis process development, analytical characterization, and formulation optimization activities.
Nanosoft is led by Dr. Xiaobing Xiong, who trained under Dr. Afsaneh Lavasanifar; both are co-inventors of Onco’s proprietary nanoparticle delivery technology. Days earlier, Onco reported producing approximately 952 grams of a key ONC010 precursor at kilogram scale through its collaboration with Dalton Pharma Services, setting the stage for the next phase of its manufacturing program.
Building Toward the Clinic
The history of cancer nanomedicine is a reminder that scientific promises and clinical reality do not always move in lockstep, and the field’s renewed momentum does not guarantee the success of any individual program. What it does suggest is that the questions now facing developers such as Onco-Innovations, surrounding delivery, formulation, scalability, and reproducibility, are increasingly becoming the right questions to ask.
As ONC010 advances toward first-in-human studies, the program reflects a broader shift underway across cancer nanomedicine, one focused not only on reducing drug toxicity but also on improving therapeutic performance. Whether that promise ultimately translates into clinical success remains to be seen, but the direction of the field is becoming increasingly clear.
For more information, visit https://oncoinnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
